Trial Profile
A Randomized, Open-Label, Single-Dose, 3-Period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Dec 2009
Price :
$35
*
At a glance
- Drugs BLI 489 (Primary) ; Piperacillin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- 18 Jul 2009 Actual end date Jul 2009 added as reported by ClinicalTrials.gov.
- 18 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2009 Additional lead trial centre and location (Philadelphia, USA) identified as reported by ClinicalTrials.gov.